|
1
|
Bromley DB: The idea of ageing: An
historical and psychological analysis. Compr Gerontol C. 2:30–41.
1988.PubMed/NCBI
|
|
2
|
Callaway E: Race to stamp out animal
plague begins. Nature. 520:139–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clifford CB and Watson J: Old enemies,
still with us after all these years. ILAR J. 49:291–302. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dillin A, Gottschling DE and Nyström T:
The good and the bad of being connected: The integrons of aging.
Curr Opin Cell Biol. 26:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marrot L and Meunier JR: Skin DNA
photodamage and its biological consequences. J Am Acad Dermatol.
58(Suppl 2): S139–S148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cawley S, Bekiranov S, Ng HH, Kapranov P,
Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J,
Williams AJ, et al: Unbiased mapping of transcription factor
binding sites along human chromosomes 21 and 22 points to
widespread regulation of noncoding RNAs. Cell. 116:499–509. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P,
Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of
p53 transcription-factor binding sites in the human genome. Cell.
124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka T, Halicka HD, Huang X, Traganos F
and Darzynkiewicz Z: Constitutive histone H2AX phosphorylation and
ATM activation, the reporters of DNA damage by endogenous oxidants.
Cell Cycle. 5:1940–1945. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao H, Tanaka T, Halicka HD, Traganos F,
Zarebski M, Dobrucki J and Darzynkiewicz Z: Cytometric assessment
of DNA damage by exogenous and endogenous oxidants reports
aging-related processes. Cytometry A. 71:905–914. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Halicka HD, Zhao H, Li J, Traganos F,
Zhang S, Lee M and Darzynkiewicz Z: Genome protective effect of
metformin as revealed by reduced level of constitutive DNA damage
signaling. Aging. 3:1028–1038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Darzynkiewicz Z, Zhao H, Halicka HD, Li J,
Lee YS, Hsieh TC and Wu JM: In search of antiaging modalities:
Evaluation of mTOR- and ROS/DNA damage-signaling by cytometry.
Cytometry A. 85:386–399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bennett WL, Maruthur NM, Singh S, Segal
JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe
P, Block L, et al: Comparative effectiveness and safety of
medications for type 2 diabetes: An update including new drugs and
2-drug combinations. Ann Intern Med. 154:602–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inzucchi SE, Bergenstal RM, Buse JB,
Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and
Matthews DR; American Diabetes Association (ADA); European
Association for the Study of Diabetes (EASD): Management of
hyperglycemia in type 2 diabetes: A patient-centered approach:
Position statement of the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD). Diabetes
Care. 35:1364–1379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kasznicki J, Sliwinska A and Drzewoski J:
Metformin in cancer prevention and therapy. Ann Transl Med.
2:572014.PubMed/NCBI
|
|
16
|
Chandel N: Four key questions about
metformin and cancer. BMC Biol. 12:852014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azvolinsky A: Repurposing to fight cancer:
The metformin-prostate cancer connection. J Natl Cancer Inst.
106:dju0302014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Athar M, Back JH, Tang X, Kim KH,
Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of
preclinical studies for human cancer prevention. Toxicol Appl
Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:493–506. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Algire C, Amrein L, Bazile M, David S,
Zakikhani M and Pollak M: Diet and tumor LKB1 expression interact
to determine sensitivity to anti-neoplastic effects of metformin in
vivo. Oncogene. 30:1174–1182. 2011. View Article : Google Scholar
|
|
22
|
Ulgherait M, Rana A, Rera M, Graniel J and
Walker DW: AMPK modulates tissue and organismal aging in a
non-cell-autonomous manner. Cell Reports. 8:1767–1780. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soleas GJ, Diamandis EP and Goldberg DM:
Wine as a biological fluid: History, production, and role in
disease prevention. J Clin Lab Anal. 11:287–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldberg DM: More on antioxidant activity
of resveratrol in red wine. Clin Chem. 42:113–114. 1996.PubMed/NCBI
|
|
26
|
Wu JM, Lu X, Guo J and Hsieh TC: Vascular
effects of resveratrol. Phytochemicals Mechanisms of Action.
Bidlack WR, Davies AJ, Lewis DS and Randolph RK: CRC Press. Meskin,
MS; pp. 145–161. 2004
|
|
27
|
Wu JM and Hsieh TC: Resveratrol: A
cardioprotective substance. Ann NY Acad Sci. 1215:16–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu JM, Hsieh TC and Wang Z:
Cardioprotection by resveratrol: A review of effects/targets in
cultured cells and animal tissues. Am J Cardiovasc Dis. 1:38–47.
2011.
|
|
29
|
Wang L, Waltenberger B, Pferschy-Wenzig
EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S,
Rollinger JM, Heiss EH, et al: Natural product agonists of
peroxisome proliferator-activated receptor gamma (PPARγ): A review.
Biochem Pharmacol. 92:73–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anisimov VN, Egormin PA, Bershtein LM,
Zabezhinskii MA, Piskunova TS, Popovich IG and Semenchenko AV:
Metformin decelerates aging and development of mammary tumors in
HER-2/neu transgenic mice. Bull Exp Biol Med. 139:721–723. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anisimov VN, Berstein LM, Egormin PA,
Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV,
Kovalenko IG, Poroshina TE, et al: Metformin slows down aging and
extends life span of female SHR mice. Cell Cycle. 7:2769–2773.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blagosklonny MV: An anti-aging drug today:
From senescence-promoting genes to anti-aging pill. Drug Discov
Today. 12:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blagosklonny MV: Validation of anti-aging
drugs by treating age-related diseases. Aging. 1:281–288. 2009.
View Article : Google Scholar
|
|
34
|
Howitz KT, Bitterman KJ, Cohen HY, Lamming
DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL,
et al: Small molecule activators of sirtuins extend Saccharomyces
cerevisiae lifespan. Nature. 425:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bauer JH, Goupil S, Garber GB and Helfand
SL: An accelerated assay for the identification of
lifespan-extending interventions in Drosophila melanogaster. Proc
Natl Acad Sci USA. 101:12980–12985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hsieh TC, Yang CJ, Lin CY, Lee YS and Wu
JM: Control of stability of cyclin D1 by quinone reductase 2 in
CWR22Rv1 prostate cancer cells. Carcinogenesis. 33:670–677. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hsieh TC, Wu P, Park S and Wu JM:
Induction of cell cycle changes and modulation of
apoptogenic/anti-apoptotic and extracellular signaling regulatory
protein expression by water extracts of I'm-Yunity (PSP). BMC
Complement Altern Med. 6:302006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hsieh TC, Kunicki J, Darzynkiewicz Z and
Wu JM: Effects of extracts of Coriolus versicolor (I'm-Yunity) on
cell-cycle progression and expression of interleukins-1 beta,-6,
and -8 in promyelocytic HL-60 leukemic cells and mitogenically
stimulated and nonstimulated human lymphocytes. J Altern Complement
Med. 8:591–602. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
DiPietrantonio AM, Hsieh TC, Olson SC and
Wu JM: Regulation of G1/S transition and induction of apoptosis in
HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer. 78:53–61.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Darzynkiewicz Z, Bedner E and Smolewski P:
Flow cytometry in analysis of cell cycle and apoptosis. Semin
Hematol. 38:179–193. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hsieh TC and Wu JM: Differential effects
on growth, cell cycle arrest, and induction of apoptosis by
resveratrol in human prostate cancer cell lines. Exp Cell Res.
249:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aziz MH, Reagan-Shaw S, Wu J, Longley BJ
and Ahmad N: Chemoprevention of skin cancer by grape constituent
resveratrol: Relevance to human disease? FASEB J. 19:1193–1195.
2005.PubMed/NCBI
|
|
43
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hadad SM, Hardie DG, Appleyard V and
Thompson AM: Effects of metformin on breast cancer cell
proliferation, the AMPK pathway and the cell cycle. Clin Transl
Oncol. 16:746–752. 2014. View Article : Google Scholar
|
|
45
|
Silvestri A, Palumbo F, Rasi I, Posca D,
Pavlidou T, Paoluzi S, Castagnoli L and Cesareni G: Metformin
induces apoptosis and downregulates pyruvate kinase M2 in breast
cancer cells only when grown in nutrient-poor conditions. PLoS One.
10:e01362502015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang X, Li X and Ren J: From French
Paradox to cancer treatment: Anti-cancer activities and mechanisms
of resveratrol. Anticancer Agents Med Chem. 14:806–825. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Coperchini F, Leporati P, Rotondi M and
Chiovato L: Expanding the therapeutic spectrum of metformin: From
diabetes to cancer. J Endocrinol Invest. 38:1047–1055. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang T, Wang L, Zhu M, Zhang L and Yan L:
Properties and molecular mechanisms of resveratrol: A review.
Pharmazie. 70:501–506. 2015.PubMed/NCBI
|
|
49
|
Pryor R and Cabreiro F: Repurposing
metformin: An old drug with new tricks in its binding pockets.
Biochem J. 471:307–322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Miles JM, Rule AD and Borlaug BA: Use of
metformin in diseases of aging. Curr Diab Rep. 14:4902014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Burkewitz K, Zhang Y and Mair WB: AMPK at
the nexus of energetics and aging. Cell Metab. 20:10–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gheghiani L and Gavet O: Spatiotemporal
investigation of phosphorylation events during cell cycle
progression. Methods Mol Biol. 1342:157–171. 2016. View Article : Google Scholar
|
|
53
|
Peter M, Le Peuch C, Labbé JC, Meyer AN,
Donoghue DJ and Dorée M: Initial activation of cyclin-B1-cdc2
kinase requires phosphorylation of cyclin B1. EMBO Rep. 3:551–556.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Halicka HD, Zhao H, Li J, Lee YS, Hsieh
TC, Wu JM and Darzynkiewicz Z: Potential anti-aging agents suppress
the level of constitutive mTOR- and DNA damage-signaling. Aging.
4:952–965. 2012. View Article : Google Scholar
|
|
55
|
McCay CM: Is longevity compatible with
optimum growth? Science. 77:410–411. 1933. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Park HW: Longevity, aging, and caloric
restriction: Clive Maine McCay and the construction of a
multidisciplinary research program. Hist Stud Nat Sci. 40:79–124.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hosono K, Endo H, Takahashi H, Sugiyama M,
Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al:
Metformin suppresses colorectal aberrant crypt foci in a short-term
clinical trial. Cancer Prev Res. 3:1077–1083. 2010. View Article : Google Scholar
|
|
60
|
Tanaka H, Arakawa H, Yamaguchi T,
Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: A
ribonucleotide reductase gene involved in a p53-dependent
cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shao J, Zhou B, Zhu L, Qiu W, Yuan YC, Xi
B and Yen Y: In vitro characterization of enzymatic properties and
inhibition of the p53R2 subunit of human ribonucleotide reductase.
Cancer Res. 64:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yen Y, Chu B, Yen C, Shih J and Zhou B:
Enzymatic property analysis of p53R2 subunit of human
ribonucleotide reductase. Adv Enzyme Regul. 46:235–247. 2006.
View Article : Google Scholar : PubMed/NCBI
|
